TMDX makes the Organ Care System (OCS) — the only FDA-approved warm perfusion platform for lung, heart, and liver transplantation. Revenue grew 21% to $174M in Q1 2026 with 60% gross margins. But Q1 was a margin disaster: net income fell 71.5% YoY to $7.3M, operating margins collapsed from 19.1% to 7.6%, and FCF turned negative (-$12M). The dossier's thesis is based on stale numbers. Short interest is 36.9% of float but days to cover dropped from 14 to 5 — shorts are covering into the decline. 9 analysts maintain Buy with $116.78 mean target (68% upside). Wait for Q2 2026 results to determine if Q1 was an aberration.
Key Metrics
Thesis
The 'value price' part of the dossier thesis is broken until margins recover. Q1 2026 net income collapsed 71.5% — trailing PE of 15.9x is a mirage built on FY2025 earnings. Forward PE is ~87x on annualized Q1 EPS. Revenue growth (21%) and gross margins (60%) are intact. The investment case now depends entirely on whether Q1's margin collapse was a one-time scaling cost or structural deterioration.
Research Memo
The Dossier Thesis Is Broken
The dossier's 'growth at value price' thesis relies on FY2025 numbers that no longer reflect reality. Q1 2026 net income fell 71.5% to $7.3M. Free cash flow turned negative. Operating margins collapsed from 19.1% to 7.6%. The trailing PE of 15.9x uses FY2025 EPS of $4.87 — but Q1 2026 annualized is $0.80/share, implying a forward PE of ~87x. The value part of the thesis evaporated in one quarter.
Revenue Growth Is Intact
$174M Q1 revenue, +21% YoY. Gross margins at 58.2% (down from ~61% but still healthy). The demand side works. The problem is entirely on the cost side — SG&A grew 42.8% while revenue grew 21%. If Q1's cost spike was National OCS Program scaling costs that normalize, the thesis survives. If SG&A growth continues outpacing revenue, it doesn't.
FDA Monopoly Provides Genuine Moat
OCS has no direct FDA-approved competitor for warm perfusion in lung/heart/liver transplantation. Cold storage is the incumbent standard but inferior. This is a genuine competitive moat. The conversion rate from cold storage to OCS is the growth driver.
Short Interest Is Elevated But Shorts Are Covering
Short interest is 36.9% of float with 8.18M shares short. Days to cover dropped from ~14 to 4.91 — shorts are covering into the selloff rather than doubling down. This reduces squeeze potential but suggests short sellers see limited additional downside from current levels.
QA Evaluation
- Memo correctly identifies that the dossier thesis is broken — the 'value price' part relied on stale FY2025 numbers
- Confidence downgraded to MEDIUM (appropriate — can't determine if margin collapse is temporary or structural)
- Missing: bull case could be steel-manned more aggressively — 60% gross margins with 21% revenue growth is genuinely strong
- Short float discrepancy flagged: 36.9% (yfinance) vs 24.5% (NASDAQ) — both numbers should be presented
Timeline
Risks
Open Questions
- Was Q1 margin collapse one-time (National OCS Program scaling) or structural?
- Short float discrepancy: 36.9% (yfinance) vs 24.5% (NASDAQ) — which is correct?
- Can 21% revenue growth continue as comps get harder?
- What is the OCS penetration rate vs cold storage — and trajectory?
Review Triggers
- Q2 2026 earnings (~August 2026) — margin recovery or further deterioration
- TMDX crosses above $90 (50-day MA) or below $60 (52-week low)
- Any FDA competitor approval in warm perfusion
Agent Notes
Dossier thesis needs update — the 'value price' language is stale. Revenue growth rate trending 83%→44%→21% — decelerating. Wait for Q2 to determine if Q1 was an aberration or the new normal.